CTOs on the Move

Signature Family Wealth

www.signaturefamilywealth.com

 
Signature is a Virginia-based multi-family office, offering clients comprehensive strategies and solutions for all aspects of their financial life. With assets under management in excess of $3.7 billion, Signature takes an intelligent approach to creating customized plans for their high net worth individuals and families.
  • Number of Employees: 1K-5K
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

EDIX12

EDIX12 is a Hicksville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Novasys Health

Novasys Health is a Little Rock, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VNA Care Network

Since 1891, VNA Care Network has helped people of all ages cope with illness and injury where they most want to be at home.

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic

Georgia Medical Care Foundation

Since 1972, GMCF has been providing medical peer review and consultative services, utilization and quality management review services for Medicaid Programs.